Those drugs target diverse molecular signals involved in CRS, such as IL-1 signaling, IL-6 signaling, TNF-α signaling, IFN-γ signaling, and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling, with some of them exhibiting promising clinical benefits (Kim et al., 2021). Here, IL6 is linked to congenital rubella syndrome.